Tiziana's lead product is foralumab, a fully human antibody. The lead indication for intranasal foralumab is non-active secondary progressive multiple sclerosis (SPMS). The first two enrolled patients in the ongoing expanded access study showed encouraging responses. With planned completion of the necessary preclinical studies in Q123, we anticipate an IND filing by mid-2023 and a Phase 2 trial starting from Q323.